2026 Q1 -tulosraportti
Vain PDF
35 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 380 | - | - | ||
| 5 000 | - | - | ||
| 1 083 | - | - | ||
| 5 000 | - | - | ||
| 1 617 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·11 t sitten · MuokattuA little info about the potential in connection with the approved patent for LIB-01 in Japan. As well as previous patent approval in the USA. It is estimated that there are over 23 million men over 50 years old in Japan in 2026. Of a total population of 122.4 million, men constitute approximately 59.6 million. The age distribution for the male population over 50 years old in Japan is approximately as follows based on demographic projections: 50–64 years: approx. 11.8 million. 65 years and older: approx. 11.3 million In 2026, it is estimated that there will be approximately 40 million men over 50 years old in the USA. Of these, there are about 20.4 million men in the 51–60 age group and approximately 19.2 million men in the 61–70 age group. Dicot Pharma Patent & Nasdaq Ruling today at 10:39 ∙ News Summary (AI) Dicot Pharma has significantly strengthened its intellectual property by securing a new patent in Japan for LIB-01, its lead drug candidate for erectile dysfunction, valid until 2043. This expands on existing protection, including a similar patent in the USA, and reinforces its market position. Concurrently, the company received a favorable ruling from Nasdaq's Disciplinary Committee, which determined Dicot Pharma did not violate regulations regarding its Phase 2a study communication, thus avoiding any sanctions. Dicot Pharma secured a new patent in Japan for its drug candidate LIB-01, valid until 2043, strengthening its intellectual property for erectile dysfunction treatment. A similar patent for LIB-01 has already been approved in the USA, with applications ongoing in several other countries.- ·12 t sittenAn important date reminder regarding the emission. From 03.06.2026 you must have funds for the entire subscription available for trading in your account. If not, the entire subscription or parts of it may be rejected. On 04.06.2026 we will withdraw the funds and give you paid subscribed units (BTU). They will be changed after approximately 2-4 weeks. One unit contains 8 AK & 2 TO7 If you subscribe for units without unit rights, the application will appear in your account on 04.06.2026. When we receive notification of a potential allocation, we will withdraw funds and allocate BTU. This normally takes 1-2 weeks.
·18 t sittenGood justification by the company why the primary endpoint is not important here and they were acquitted with good reason. https://www.nasdaq.com/docs/2026/06/03/2026-08_Dicot_Pharma_AB_Beslut.pdf
·12 t sittenInteresting that you got into dicot what was the dealbreaker ?
·1 päivä sittenThe short sellers are celebrating 🤨 I don't think short interest has ever been this high in this stock 2.62% 😡
·1 päivä sittenThen it will soon be crowded at the door when they are to buy back in again. You should surely know that the short sellers must return borrowed shares.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
35 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 t sitten · MuokattuA little info about the potential in connection with the approved patent for LIB-01 in Japan. As well as previous patent approval in the USA. It is estimated that there are over 23 million men over 50 years old in Japan in 2026. Of a total population of 122.4 million, men constitute approximately 59.6 million. The age distribution for the male population over 50 years old in Japan is approximately as follows based on demographic projections: 50–64 years: approx. 11.8 million. 65 years and older: approx. 11.3 million In 2026, it is estimated that there will be approximately 40 million men over 50 years old in the USA. Of these, there are about 20.4 million men in the 51–60 age group and approximately 19.2 million men in the 61–70 age group. Dicot Pharma Patent & Nasdaq Ruling today at 10:39 ∙ News Summary (AI) Dicot Pharma has significantly strengthened its intellectual property by securing a new patent in Japan for LIB-01, its lead drug candidate for erectile dysfunction, valid until 2043. This expands on existing protection, including a similar patent in the USA, and reinforces its market position. Concurrently, the company received a favorable ruling from Nasdaq's Disciplinary Committee, which determined Dicot Pharma did not violate regulations regarding its Phase 2a study communication, thus avoiding any sanctions. Dicot Pharma secured a new patent in Japan for its drug candidate LIB-01, valid until 2043, strengthening its intellectual property for erectile dysfunction treatment. A similar patent for LIB-01 has already been approved in the USA, with applications ongoing in several other countries.
- ·12 t sittenAn important date reminder regarding the emission. From 03.06.2026 you must have funds for the entire subscription available for trading in your account. If not, the entire subscription or parts of it may be rejected. On 04.06.2026 we will withdraw the funds and give you paid subscribed units (BTU). They will be changed after approximately 2-4 weeks. One unit contains 8 AK & 2 TO7 If you subscribe for units without unit rights, the application will appear in your account on 04.06.2026. When we receive notification of a potential allocation, we will withdraw funds and allocate BTU. This normally takes 1-2 weeks.
- ·18 t sittenGood justification by the company why the primary endpoint is not important here and they were acquitted with good reason. https://www.nasdaq.com/docs/2026/06/03/2026-08_Dicot_Pharma_AB_Beslut.pdf·12 t sittenInteresting that you got into dicot what was the dealbreaker ?
- ·1 päivä sittenThe short sellers are celebrating 🤨 I don't think short interest has ever been this high in this stock 2.62% 😡·1 päivä sittenThen it will soon be crowded at the door when they are to buy back in again. You should surely know that the short sellers must return borrowed shares.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 380 | - | - | ||
| 5 000 | - | - | ||
| 1 083 | - | - | ||
| 5 000 | - | - | ||
| 1 617 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
35 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 t sitten · MuokattuA little info about the potential in connection with the approved patent for LIB-01 in Japan. As well as previous patent approval in the USA. It is estimated that there are over 23 million men over 50 years old in Japan in 2026. Of a total population of 122.4 million, men constitute approximately 59.6 million. The age distribution for the male population over 50 years old in Japan is approximately as follows based on demographic projections: 50–64 years: approx. 11.8 million. 65 years and older: approx. 11.3 million In 2026, it is estimated that there will be approximately 40 million men over 50 years old in the USA. Of these, there are about 20.4 million men in the 51–60 age group and approximately 19.2 million men in the 61–70 age group. Dicot Pharma Patent & Nasdaq Ruling today at 10:39 ∙ News Summary (AI) Dicot Pharma has significantly strengthened its intellectual property by securing a new patent in Japan for LIB-01, its lead drug candidate for erectile dysfunction, valid until 2043. This expands on existing protection, including a similar patent in the USA, and reinforces its market position. Concurrently, the company received a favorable ruling from Nasdaq's Disciplinary Committee, which determined Dicot Pharma did not violate regulations regarding its Phase 2a study communication, thus avoiding any sanctions. Dicot Pharma secured a new patent in Japan for its drug candidate LIB-01, valid until 2043, strengthening its intellectual property for erectile dysfunction treatment. A similar patent for LIB-01 has already been approved in the USA, with applications ongoing in several other countries.
- ·12 t sittenAn important date reminder regarding the emission. From 03.06.2026 you must have funds for the entire subscription available for trading in your account. If not, the entire subscription or parts of it may be rejected. On 04.06.2026 we will withdraw the funds and give you paid subscribed units (BTU). They will be changed after approximately 2-4 weeks. One unit contains 8 AK & 2 TO7 If you subscribe for units without unit rights, the application will appear in your account on 04.06.2026. When we receive notification of a potential allocation, we will withdraw funds and allocate BTU. This normally takes 1-2 weeks.
- ·18 t sittenGood justification by the company why the primary endpoint is not important here and they were acquitted with good reason. https://www.nasdaq.com/docs/2026/06/03/2026-08_Dicot_Pharma_AB_Beslut.pdf·12 t sittenInteresting that you got into dicot what was the dealbreaker ?
- ·1 päivä sittenThe short sellers are celebrating 🤨 I don't think short interest has ever been this high in this stock 2.62% 😡·1 päivä sittenThen it will soon be crowded at the door when they are to buy back in again. You should surely know that the short sellers must return borrowed shares.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 380 | - | - | ||
| 5 000 | - | - | ||
| 1 083 | - | - | ||
| 5 000 | - | - | ||
| 1 617 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt